Autorentext

Dr. Manish K. Chourasia, is currently working as a Senior Principal Scientist in the Division of Pharmaceutics and Pharmacokinetics at CSIR-Central Drug Research Institute (CDRI), Lucknow, a premium drug research institute in India. He received his PhD in Pharmaceutical Sciences from Dr. Harisingh Gour University, Madhya Pradesh, India and carried out his post-doctoral studies at Department of Pharmacy, National University of Singapore, Singapore. Having acquired valuable experience in both industry and academia, he subsequently joined the role of a scientist at CSIR-CDRI almost two decades ago. He has played a significant role in advancing the field of nanoparticle-based drug delivery for breast cancer, aiming to enhance the therapeutic outcome. He has published 80+ scientific papers including high-impact journal reviews. He has supervised more than 50 MS students and PhD students.

Prof. Shubhini A. Saraf is working as Director of the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli (U.P.). Before joining NIPER, Raebareli, she worked as a Professor in the Department of Pharmaceutical Sciences and Director (R&D) at Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow. She also served in various administrative positions at BBA University Lucknow and B.B.D.N.I.T.M. Lucknow including Head-Pharmaceutical Sciences, Dean- School of Biomedical and Pharmaceutical Sciences, Dean- School of Biosciences & Biotechnology, member of the Board of Management, Director, E.M.M.R.C. at BBAU, Lucknow and Director B.B.D.N.I.T.M. Lucknow. Prof. Shubhini is an alumnus of the Department of Pharmaceutical Sciences, Dr Harisingh Gour University, Sagar where she pursued her B. Pharm, M. Pharm, and Ph.D. in Pharmacy. She has more than 28 years of teaching and research experience. Her research interests include Nanotechnology & Drug Targeting as well as Technology Policy Interventions for Health Care. She has 167 papers, and 21 book chapters to her credit and is an active pharmacy professional.

Yashwant Pathak is a Professor and Associate Dean for faculty affairs at the Taneja College of Pharmacy at the University of South Florida, Tampa, USA. Prof. Pathak is also an Adjunct Professor at the Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia. His area of research is in health care education, nanotechnology, drug delivery systems, and nutraceuticals.Dr. Mohini Chaurasia stands as a distinguished figure in the field of pharmaceutical education, currently holding the positions of Professor and Principal at Era College of Pharmacy, Era University, Lucknow, India. With a career spanning various academic institutions, including Amity University and Integral University, Dr. Chaurasia has garnered extensive experience, contributing significantly to the field. Her academic journey boasts a culmination in her current role, driving both research and institutional leadership. Dr. Chaurasia's expertise extends beyond teaching to innovative research, evident in her publications and patents. In the field of drug delivery, she has edited books like "Novel Carriers for Drug Delivery" and "Oral Modified Release Drug Delivery Systems," showcasing her depth of knowledge. Moreover, her research contributions include impactful chapters on drug delivery systems and nanotechnology applications in drug development. Beyond her scholarly pursuits, Dr. Chaurasia actively engages in various academic and administrative responsibilities, serving on boards, committees, and taking up leadership roles.

Klappentext

Nanotherapeutics for Treating Neurodegenerative Disorders is a comprehensive guide to the cutting-edge field of nanotherapeutics. This book reviews the complex landscape of neurodegenerative disorders, outlining the nuances of treatment strategies and the imperative role of nanotechnology in revolutionizing therapeutic interventions. From explaining the transport mechanisms of the Blood-Brain Barrier to unveiling the therapeutic potential of stem cell-derived nanocarriers, each chapter offers invaluable insights into the diverse array of nanotherapeutic approaches helping to reshape the landscape of neurological healthcare. By consolidating current updates on advanced targets-based nanotherapeutics, this book provides a comprehensive resource for neurodegenerative diseases converge. Whether seeking to unravel the complexities of mitochondrial dysfunction or harness the potential of nanocarriers for targeted genetic material delivery, readers will find themselves equipped with the tools to navigate the forefront of neurotherapeutic innovation.

Inhalt

1. Concepts, types, and treatment strategies for neurodegenerative disorders
   
   2. Transport mechanisms of the Blood-Brain Barrier
   3. Need of nanotherapeutics against neurodegenerative disorders
   4. Nanotechnology mediated drug delivery for addressing protein aggregation
   5. Nanocarriers focusing on synuclein misfolding as a therapeutic target
   6. Therapeutic potential of stem cells derived nanocarriers in neurological disorders
   7. Emphasizing mitochondrial dysfunction and autophagy in the treatment of neurological disorders
   8. Nanocarriers assisted delivery of genetic material for the treatment of neurodegenerative disorders
   9. Nanotherapeutics targeting neuroinflammation
   10. Nanocarriers mediated DNA repair mechanism against neurological disorders
   11. Nanotherapy for targeted inhibition of PERK: Unravelling stress-induced endoplasmic reticulum kinase
   12. Targeting microglial inhibition via nanotechnology: A strategy to halt protein degradation
   13. Nanocarriers unveiling ferroptosis as a potential therapeutic target
   14. Proteostasis maintenance through nanocarriers: Mitigating protein misfolding, mitochondrial impairment, and oxidative stress
   15. Modulation of Hippo signaling pathway dysregulation through nanotechnology for neurodegenerative disorders
   16. Nanocarriers modulating fibrinolytic pathways for the treatment of various neurological disorders
   17. Targeting glial cells through nanotherapeutic strategies in neurological disorders
   18. Oligodendrocytes as an emerging therapeutic target in neurological disorders